Asya Nina Varshavsky-Yanovsky, MD, PhD
Clinical Locations
Primary Location
Fox Chase–Temple University Hospital Bone Marrow Transplant Program
Temple University Hospital – Jeanes Campus
Patient Care Center, Fifth Floor
7600 Central Avenue
Philadelphia, PA 19111
Assistant Professor, Department of Hematology/Oncology
Fox Chase-Temple University Hospital Bone Marrow Transplant Program
Treatment Focus
Stem cell transplant, cellular therapies
Language(s) Other than English
Treatment Philosophy
After completing my fellowship at Fox Chase, I’m delighted to continue my career here, joining the collaborative team of outstanding clinicians and researchers, dedicated to providing best care to our patients. My philosophy of care is to treat every patient like family. This means educating them fully about their treatment options and helping them make the right decision for the best possible outcome. A diagnosis of cancer can be challenging to deal with, but with a caring, experienced team behind a patient, the journey can feel less stressful.
Educational Background
- Fellow, Fox Chase/ Temple Hematology/ Oncology, Philadelphia, PA, 2016-19
- Jacobi/Albert Einstein College of Medicine, Intern and Resident in Internal Medicine Bronx, NY, 2013–16
- MD, Technion, Haifa, Israel, 2012
- PhD, Medicine, Technion, Haifa, Israel , 2009
- BSc, Medicine, Technion, Haifa, Israel, 2004
Certifications
- ABIM Internal Medicine
Honors & Awards
- The Hershel Rich Innovation Award for outstanding research projects, 2011
- Top 5% Medicine graduates in Israel, 2011
- Zieff Fine Neeman scholarship award for distinguished students, 2007
Selected Publications
Pooja Ghatalia, Chad H. Smith, Arthur Winer, Jiangtao Gou , Lesli A. Kiedrowski, Michael Slifker, Patricia D. Saltzberg, Nicole Bubes, Fern M. Anari, Vineela Kasireddy, Asya Varshavsky , Yang Liu, Eric A. Ross, Wafik S. El-Deiry Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Frontiers in Oncology 2019.
Shastri, A., Schinke, C., Varshavsky Yanovsky, A., Bhagat, T. D., Giricz, O.,Barreyro, L., Boultwood, J., Pellagati, A., Yu, Y., Brown, J. R., Frank, D. A.,Das, B., Kambhampati, S., Will, B., Steidl, U., & Verma, A Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. Blood 2014, 124(21).
Kigel B, Rabinowicz N, Varshavsky A, Kessler O, Neufeld G (2011) Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood. 2011 Aug 10.
Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin like pro-protein convertases. Cancer research, 68, 6922-6931.
Kigel B, Varshavsky A, Kessler O, Neufeld, G (2008) Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PlosOne, 3, e3287.
Gutmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G (2007) Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J. Biol. Chem., 282, 26294-26305.
Neufeld G, Lange T, Varshavsky A, Kessler O (2006) Semaphorin signaling in vascular and tumor biology. Adv. Exp. Med. Biol. 600, 118-131.
Clinical Locations
Primary Location
Fox Chase–Temple University Hospital Bone Marrow Transplant Program
Temple University Hospital – Jeanes Campus
Patient Care Center, Fifth Floor
7600 Central Avenue
Philadelphia, PA 19111
Assistant Professor, Department of Hematology/Oncology
Fox Chase-Temple University Hospital Bone Marrow Transplant Program
Treatment Focus
Stem cell transplant, cellular therapies
Language(s) Other than English
Treatment Philosophy
After completing my fellowship at Fox Chase, I’m delighted to continue my career here, joining the collaborative team of outstanding clinicians and researchers, dedicated to providing best care to our patients. My philosophy of care is to treat every patient like family. This means educating them fully about their treatment options and helping them make the right decision for the best possible outcome. A diagnosis of cancer can be challenging to deal with, but with a caring, experienced team behind a patient, the journey can feel less stressful.
Education
Educational Background
- Fellow, Fox Chase/ Temple Hematology/ Oncology, Philadelphia, PA, 2016-19
- Jacobi/Albert Einstein College of Medicine, Intern and Resident in Internal Medicine Bronx, NY, 2013–16
- MD, Technion, Haifa, Israel, 2012
- PhD, Medicine, Technion, Haifa, Israel , 2009
- BSc, Medicine, Technion, Haifa, Israel, 2004
Certifications
- ABIM Internal Medicine
Honors & Awards
- The Hershel Rich Innovation Award for outstanding research projects, 2011
- Top 5% Medicine graduates in Israel, 2011
- Zieff Fine Neeman scholarship award for distinguished students, 2007
Publications
Selected Publications
Pooja Ghatalia, Chad H. Smith, Arthur Winer, Jiangtao Gou , Lesli A. Kiedrowski, Michael Slifker, Patricia D. Saltzberg, Nicole Bubes, Fern M. Anari, Vineela Kasireddy, Asya Varshavsky , Yang Liu, Eric A. Ross, Wafik S. El-Deiry Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Frontiers in Oncology 2019.
Shastri, A., Schinke, C., Varshavsky Yanovsky, A., Bhagat, T. D., Giricz, O.,Barreyro, L., Boultwood, J., Pellagati, A., Yu, Y., Brown, J. R., Frank, D. A.,Das, B., Kambhampati, S., Will, B., Steidl, U., & Verma, A Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. Blood 2014, 124(21).
Kigel B, Rabinowicz N, Varshavsky A, Kessler O, Neufeld G (2011) Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood. 2011 Aug 10.
Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin like pro-protein convertases. Cancer research, 68, 6922-6931.
Kigel B, Varshavsky A, Kessler O, Neufeld, G (2008) Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PlosOne, 3, e3287.
Gutmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G (2007) Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J. Biol. Chem., 282, 26294-26305.
Neufeld G, Lange T, Varshavsky A, Kessler O (2006) Semaphorin signaling in vascular and tumor biology. Adv. Exp. Med. Biol. 600, 118-131.